human mrna microarray v2.0 gene chip Search Results


93
GE Healthcare microarray hybridization
Microarray Hybridization, supplied by GE Healthcare, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/microarray hybridization/product/GE Healthcare
Average 93 stars, based on 1 article reviews
microarray hybridization - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

90
Arraystar inc human lncrna microarray v2.0
Human Lncrna Microarray V2.0, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human lncrna microarray v2.0/product/Arraystar inc
Average 90 stars, based on 1 article reviews
human lncrna microarray v2.0 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
CDI Laboratories human proteome microarray version 2.0
Human Proteome Microarray Version 2.0, supplied by CDI Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human proteome microarray version 2.0/product/CDI Laboratories
Average 90 stars, based on 1 article reviews
human proteome microarray version 2.0 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
CapitalBio Corporation human mrna microarray v2.0
Human Mrna Microarray V2.0, supplied by CapitalBio Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human mrna microarray v2.0/product/CapitalBio Corporation
Average 90 stars, based on 1 article reviews
human mrna microarray v2.0 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Arraystar inc human circrna v2.0 microarray
<t>CircRNA</t> <t>microarray</t> and screening process. Results from circRNA microarray and bioinformatics analysis from five paired human RCC vs. RBM tissues were summarized in (A‐D). (A) Box plot demonstrated no significant differences in the distribution of intensity across 10 clinical samples. (B) Scatter plot displayed circRNAs expression correlation between RCC and RBM group. (C) Heat map generated from circRNAs microarray data reflecting circRNAs expression values in RCC and RBM groups. (D) Volcano plot showing DERs data. The red points indicate points‐of‐interest that display both large magnitude fold‐changes (x‐axis) and high statistical significance (‐log10 of p ‐value, y‐axis). The green line shows points above the line having p < 0.05 and points below the line having p > 0.05. This plot is colored such that those points having a fold‐change less than 2 (log2 = 1) are shown in gray. (E) The qRT‐PCR was performed to show 32 selected candidate circRNAs expression levels in cells. (F) The qRT‐PCR was performed on SW839 cells to show effects of manipulating efficiency of selected candidate circRNAs, ciR4#, ciR6#, ciR19#, and ciR26#. (G‐J) Interruption assays revealed that suppressing (G) ciR‐4# (hsa_circ_0001275), (H) ciR‐6# (hsa_circRNA_405974), expression cannot reverse/block the knocked‐down AR‐increased osteolytic formation in SW839 cells (scale bars, 200 μm), increasing (I) ciR‐19# (hsa_circ_0091743) expression, and (J) increasing ciR‐26# hsa_circ_0075303 expression cannot reverse/block the AR‐suppressed osteolytic formation in SW839 cell line (scale bars, 200 μm). For (E‐J), quantitation is at the right, and data are presented as Mean ± SD, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Abbreviation: N.S., not significant
Human Circrna V2.0 Microarray, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human circrna v2.0 microarray/product/Arraystar inc
Average 90 stars, based on 1 article reviews
human circrna v2.0 microarray - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
CapitalBio Corporation human 22k oligo microarray v. 2.0
<t>CircRNA</t> <t>microarray</t> and screening process. Results from circRNA microarray and bioinformatics analysis from five paired human RCC vs. RBM tissues were summarized in (A‐D). (A) Box plot demonstrated no significant differences in the distribution of intensity across 10 clinical samples. (B) Scatter plot displayed circRNAs expression correlation between RCC and RBM group. (C) Heat map generated from circRNAs microarray data reflecting circRNAs expression values in RCC and RBM groups. (D) Volcano plot showing DERs data. The red points indicate points‐of‐interest that display both large magnitude fold‐changes (x‐axis) and high statistical significance (‐log10 of p ‐value, y‐axis). The green line shows points above the line having p < 0.05 and points below the line having p > 0.05. This plot is colored such that those points having a fold‐change less than 2 (log2 = 1) are shown in gray. (E) The qRT‐PCR was performed to show 32 selected candidate circRNAs expression levels in cells. (F) The qRT‐PCR was performed on SW839 cells to show effects of manipulating efficiency of selected candidate circRNAs, ciR4#, ciR6#, ciR19#, and ciR26#. (G‐J) Interruption assays revealed that suppressing (G) ciR‐4# (hsa_circ_0001275), (H) ciR‐6# (hsa_circRNA_405974), expression cannot reverse/block the knocked‐down AR‐increased osteolytic formation in SW839 cells (scale bars, 200 μm), increasing (I) ciR‐19# (hsa_circ_0091743) expression, and (J) increasing ciR‐26# hsa_circ_0075303 expression cannot reverse/block the AR‐suppressed osteolytic formation in SW839 cell line (scale bars, 200 μm). For (E‐J), quantitation is at the right, and data are presented as Mean ± SD, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Abbreviation: N.S., not significant
Human 22k Oligo Microarray V. 2.0, supplied by CapitalBio Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human 22k oligo microarray v. 2.0/product/CapitalBio Corporation
Average 90 stars, based on 1 article reviews
human 22k oligo microarray v. 2.0 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Arraystar inc human circular rna microarray v2.0 chips
<t>CircRNA</t> <t>microarray</t> and screening process. Results from circRNA microarray and bioinformatics analysis from five paired human RCC vs. RBM tissues were summarized in (A‐D). (A) Box plot demonstrated no significant differences in the distribution of intensity across 10 clinical samples. (B) Scatter plot displayed circRNAs expression correlation between RCC and RBM group. (C) Heat map generated from circRNAs microarray data reflecting circRNAs expression values in RCC and RBM groups. (D) Volcano plot showing DERs data. The red points indicate points‐of‐interest that display both large magnitude fold‐changes (x‐axis) and high statistical significance (‐log10 of p ‐value, y‐axis). The green line shows points above the line having p < 0.05 and points below the line having p > 0.05. This plot is colored such that those points having a fold‐change less than 2 (log2 = 1) are shown in gray. (E) The qRT‐PCR was performed to show 32 selected candidate circRNAs expression levels in cells. (F) The qRT‐PCR was performed on SW839 cells to show effects of manipulating efficiency of selected candidate circRNAs, ciR4#, ciR6#, ciR19#, and ciR26#. (G‐J) Interruption assays revealed that suppressing (G) ciR‐4# (hsa_circ_0001275), (H) ciR‐6# (hsa_circRNA_405974), expression cannot reverse/block the knocked‐down AR‐increased osteolytic formation in SW839 cells (scale bars, 200 μm), increasing (I) ciR‐19# (hsa_circ_0091743) expression, and (J) increasing ciR‐26# hsa_circ_0075303 expression cannot reverse/block the AR‐suppressed osteolytic formation in SW839 cell line (scale bars, 200 μm). For (E‐J), quantitation is at the right, and data are presented as Mean ± SD, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Abbreviation: N.S., not significant
Human Circular Rna Microarray V2.0 Chips, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human circular rna microarray v2.0 chips/product/Arraystar inc
Average 90 stars, based on 1 article reviews
human circular rna microarray v2.0 chips - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Arraystar inc human gene expression microarray
<t>CircRNA</t> <t>microarray</t> and screening process. Results from circRNA microarray and bioinformatics analysis from five paired human RCC vs. RBM tissues were summarized in (A‐D). (A) Box plot demonstrated no significant differences in the distribution of intensity across 10 clinical samples. (B) Scatter plot displayed circRNAs expression correlation between RCC and RBM group. (C) Heat map generated from circRNAs microarray data reflecting circRNAs expression values in RCC and RBM groups. (D) Volcano plot showing DERs data. The red points indicate points‐of‐interest that display both large magnitude fold‐changes (x‐axis) and high statistical significance (‐log10 of p ‐value, y‐axis). The green line shows points above the line having p < 0.05 and points below the line having p > 0.05. This plot is colored such that those points having a fold‐change less than 2 (log2 = 1) are shown in gray. (E) The qRT‐PCR was performed to show 32 selected candidate circRNAs expression levels in cells. (F) The qRT‐PCR was performed on SW839 cells to show effects of manipulating efficiency of selected candidate circRNAs, ciR4#, ciR6#, ciR19#, and ciR26#. (G‐J) Interruption assays revealed that suppressing (G) ciR‐4# (hsa_circ_0001275), (H) ciR‐6# (hsa_circRNA_405974), expression cannot reverse/block the knocked‐down AR‐increased osteolytic formation in SW839 cells (scale bars, 200 μm), increasing (I) ciR‐19# (hsa_circ_0091743) expression, and (J) increasing ciR‐26# hsa_circ_0075303 expression cannot reverse/block the AR‐suppressed osteolytic formation in SW839 cell line (scale bars, 200 μm). For (E‐J), quantitation is at the right, and data are presented as Mean ± SD, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Abbreviation: N.S., not significant
Human Gene Expression Microarray, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human gene expression microarray/product/Arraystar inc
Average 90 stars, based on 1 article reviews
human gene expression microarray - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Arraystar inc human incrna array v2.0; 8×60k
<t>CircRNA</t> <t>microarray</t> and screening process. Results from circRNA microarray and bioinformatics analysis from five paired human RCC vs. RBM tissues were summarized in (A‐D). (A) Box plot demonstrated no significant differences in the distribution of intensity across 10 clinical samples. (B) Scatter plot displayed circRNAs expression correlation between RCC and RBM group. (C) Heat map generated from circRNAs microarray data reflecting circRNAs expression values in RCC and RBM groups. (D) Volcano plot showing DERs data. The red points indicate points‐of‐interest that display both large magnitude fold‐changes (x‐axis) and high statistical significance (‐log10 of p ‐value, y‐axis). The green line shows points above the line having p < 0.05 and points below the line having p > 0.05. This plot is colored such that those points having a fold‐change less than 2 (log2 = 1) are shown in gray. (E) The qRT‐PCR was performed to show 32 selected candidate circRNAs expression levels in cells. (F) The qRT‐PCR was performed on SW839 cells to show effects of manipulating efficiency of selected candidate circRNAs, ciR4#, ciR6#, ciR19#, and ciR26#. (G‐J) Interruption assays revealed that suppressing (G) ciR‐4# (hsa_circ_0001275), (H) ciR‐6# (hsa_circRNA_405974), expression cannot reverse/block the knocked‐down AR‐increased osteolytic formation in SW839 cells (scale bars, 200 μm), increasing (I) ciR‐19# (hsa_circ_0091743) expression, and (J) increasing ciR‐26# hsa_circ_0075303 expression cannot reverse/block the AR‐suppressed osteolytic formation in SW839 cell line (scale bars, 200 μm). For (E‐J), quantitation is at the right, and data are presented as Mean ± SD, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Abbreviation: N.S., not significant
Human Incrna Array V2.0; 8×60k, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human incrna array v2.0; 8×60k/product/Arraystar inc
Average 90 stars, based on 1 article reviews
human incrna array v2.0; 8×60k - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
CDI Laboratories huprot human proteome microarray v2.0
<t>CircRNA</t> <t>microarray</t> and screening process. Results from circRNA microarray and bioinformatics analysis from five paired human RCC vs. RBM tissues were summarized in (A‐D). (A) Box plot demonstrated no significant differences in the distribution of intensity across 10 clinical samples. (B) Scatter plot displayed circRNAs expression correlation between RCC and RBM group. (C) Heat map generated from circRNAs microarray data reflecting circRNAs expression values in RCC and RBM groups. (D) Volcano plot showing DERs data. The red points indicate points‐of‐interest that display both large magnitude fold‐changes (x‐axis) and high statistical significance (‐log10 of p ‐value, y‐axis). The green line shows points above the line having p < 0.05 and points below the line having p > 0.05. This plot is colored such that those points having a fold‐change less than 2 (log2 = 1) are shown in gray. (E) The qRT‐PCR was performed to show 32 selected candidate circRNAs expression levels in cells. (F) The qRT‐PCR was performed on SW839 cells to show effects of manipulating efficiency of selected candidate circRNAs, ciR4#, ciR6#, ciR19#, and ciR26#. (G‐J) Interruption assays revealed that suppressing (G) ciR‐4# (hsa_circ_0001275), (H) ciR‐6# (hsa_circRNA_405974), expression cannot reverse/block the knocked‐down AR‐increased osteolytic formation in SW839 cells (scale bars, 200 μm), increasing (I) ciR‐19# (hsa_circ_0091743) expression, and (J) increasing ciR‐26# hsa_circ_0075303 expression cannot reverse/block the AR‐suppressed osteolytic formation in SW839 cell line (scale bars, 200 μm). For (E‐J), quantitation is at the right, and data are presented as Mean ± SD, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Abbreviation: N.S., not significant
Huprot Human Proteome Microarray V2.0, supplied by CDI Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/huprot human proteome microarray v2.0/product/CDI Laboratories
Average 90 stars, based on 1 article reviews
huprot human proteome microarray v2.0 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
CapitalBio Corporation circrna human gene expression microarray v2.0
Study flow chart. First, the difference of <t>circRNA</t> expression profiles between anti‐tuberculosis drug‐induced liver injury (ADLI) and non‐ADLI patients were explored. Then, a differentially expressed circRNA was selected for verification in a cohort of 300 patients. Finally, the function of this circRNA was verified in a self‐controlled cohort of 35 patients based on the results of the experimental study
Circrna Human Gene Expression Microarray V2.0, supplied by CapitalBio Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/circrna human gene expression microarray v2.0/product/CapitalBio Corporation
Average 90 stars, based on 1 article reviews
circrna human gene expression microarray v2.0 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Operon Biotech 22k human v2.0 oligo microarray
Study flow chart. First, the difference of <t>circRNA</t> expression profiles between anti‐tuberculosis drug‐induced liver injury (ADLI) and non‐ADLI patients were explored. Then, a differentially expressed circRNA was selected for verification in a cohort of 300 patients. Finally, the function of this circRNA was verified in a self‐controlled cohort of 35 patients based on the results of the experimental study
22k Human V2.0 Oligo Microarray, supplied by Operon Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/22k human v2.0 oligo microarray/product/Operon Biotech
Average 90 stars, based on 1 article reviews
22k human v2.0 oligo microarray - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


CircRNA microarray and screening process. Results from circRNA microarray and bioinformatics analysis from five paired human RCC vs. RBM tissues were summarized in (A‐D). (A) Box plot demonstrated no significant differences in the distribution of intensity across 10 clinical samples. (B) Scatter plot displayed circRNAs expression correlation between RCC and RBM group. (C) Heat map generated from circRNAs microarray data reflecting circRNAs expression values in RCC and RBM groups. (D) Volcano plot showing DERs data. The red points indicate points‐of‐interest that display both large magnitude fold‐changes (x‐axis) and high statistical significance (‐log10 of p ‐value, y‐axis). The green line shows points above the line having p < 0.05 and points below the line having p > 0.05. This plot is colored such that those points having a fold‐change less than 2 (log2 = 1) are shown in gray. (E) The qRT‐PCR was performed to show 32 selected candidate circRNAs expression levels in cells. (F) The qRT‐PCR was performed on SW839 cells to show effects of manipulating efficiency of selected candidate circRNAs, ciR4#, ciR6#, ciR19#, and ciR26#. (G‐J) Interruption assays revealed that suppressing (G) ciR‐4# (hsa_circ_0001275), (H) ciR‐6# (hsa_circRNA_405974), expression cannot reverse/block the knocked‐down AR‐increased osteolytic formation in SW839 cells (scale bars, 200 μm), increasing (I) ciR‐19# (hsa_circ_0091743) expression, and (J) increasing ciR‐26# hsa_circ_0075303 expression cannot reverse/block the AR‐suppressed osteolytic formation in SW839 cell line (scale bars, 200 μm). For (E‐J), quantitation is at the right, and data are presented as Mean ± SD, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Abbreviation: N.S., not significant

Journal: Clinical and Translational Medicine

Article Title: Androgen receptor decreases the renal cell carcinoma bone metastases via suppressing the osteolytic formation through altering a novel circEXOC7 regulatory axis

doi: 10.1002/ctm2.353

Figure Lengend Snippet: CircRNA microarray and screening process. Results from circRNA microarray and bioinformatics analysis from five paired human RCC vs. RBM tissues were summarized in (A‐D). (A) Box plot demonstrated no significant differences in the distribution of intensity across 10 clinical samples. (B) Scatter plot displayed circRNAs expression correlation between RCC and RBM group. (C) Heat map generated from circRNAs microarray data reflecting circRNAs expression values in RCC and RBM groups. (D) Volcano plot showing DERs data. The red points indicate points‐of‐interest that display both large magnitude fold‐changes (x‐axis) and high statistical significance (‐log10 of p ‐value, y‐axis). The green line shows points above the line having p < 0.05 and points below the line having p > 0.05. This plot is colored such that those points having a fold‐change less than 2 (log2 = 1) are shown in gray. (E) The qRT‐PCR was performed to show 32 selected candidate circRNAs expression levels in cells. (F) The qRT‐PCR was performed on SW839 cells to show effects of manipulating efficiency of selected candidate circRNAs, ciR4#, ciR6#, ciR19#, and ciR26#. (G‐J) Interruption assays revealed that suppressing (G) ciR‐4# (hsa_circ_0001275), (H) ciR‐6# (hsa_circRNA_405974), expression cannot reverse/block the knocked‐down AR‐increased osteolytic formation in SW839 cells (scale bars, 200 μm), increasing (I) ciR‐19# (hsa_circ_0091743) expression, and (J) increasing ciR‐26# hsa_circ_0075303 expression cannot reverse/block the AR‐suppressed osteolytic formation in SW839 cell line (scale bars, 200 μm). For (E‐J), quantitation is at the right, and data are presented as Mean ± SD, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Abbreviation: N.S., not significant

Article Snippet: In the current study, five human RCC and five RCC bone metastasis tissues were deeply sequenced using Arraystar human circRNA V2.0 microarray.

Techniques: Microarray, Expressing, Generated, Quantitative RT-PCR, Blocking Assay, Quantitation Assay

The expression of circEXOC7 is regulated by DHX9. (A) The qRT‐PCR was performed on SW839 and OS‐RC‐2 cell lines to show correlation between AR and four genes related to circRNA biogenesis. Among them, ADAR2 and DHX9 have a positive correlation with AR mRNA expression. (B and C) The qRT‐qPCR was performed to show (B) knocking down DHX9, and not (C) ADAR2 gene, led to increased circEXOC7 expression in SW839 cells. (D) WB was performed on SW839 and OS‐RC‐2 cells to show that modulated AR expression also altered DHX9 expression. (E) Predicted AR binding sites on the DHX9 promoter region using website http://jaspar.genereg.net/ . (F) ChIP assay showing AR could bind to the No. 2 potential ARE on the DHX9 5′‐promoter region. (G) The wild type and mutant pGL3‐DHX9 promoter reporter constructs. (H and I) Luciferase activity after transfection of wild type or mutant DHX9 promoter reporter constructs in OS‐RC‐2 cells (H) transfected with AR‐cDNA or pWPI and SW839 cells (I) transfected with AR‐shRNA or pLKO. For (B and C), (H and I), data are presented as Mean ± SD, * p < 0.05, ** p < 0.01, *** p < 0.001. Abbreviation: N.S., not significant

Journal: Clinical and Translational Medicine

Article Title: Androgen receptor decreases the renal cell carcinoma bone metastases via suppressing the osteolytic formation through altering a novel circEXOC7 regulatory axis

doi: 10.1002/ctm2.353

Figure Lengend Snippet: The expression of circEXOC7 is regulated by DHX9. (A) The qRT‐PCR was performed on SW839 and OS‐RC‐2 cell lines to show correlation between AR and four genes related to circRNA biogenesis. Among them, ADAR2 and DHX9 have a positive correlation with AR mRNA expression. (B and C) The qRT‐qPCR was performed to show (B) knocking down DHX9, and not (C) ADAR2 gene, led to increased circEXOC7 expression in SW839 cells. (D) WB was performed on SW839 and OS‐RC‐2 cells to show that modulated AR expression also altered DHX9 expression. (E) Predicted AR binding sites on the DHX9 promoter region using website http://jaspar.genereg.net/ . (F) ChIP assay showing AR could bind to the No. 2 potential ARE on the DHX9 5′‐promoter region. (G) The wild type and mutant pGL3‐DHX9 promoter reporter constructs. (H and I) Luciferase activity after transfection of wild type or mutant DHX9 promoter reporter constructs in OS‐RC‐2 cells (H) transfected with AR‐cDNA or pWPI and SW839 cells (I) transfected with AR‐shRNA or pLKO. For (B and C), (H and I), data are presented as Mean ± SD, * p < 0.05, ** p < 0.01, *** p < 0.001. Abbreviation: N.S., not significant

Article Snippet: In the current study, five human RCC and five RCC bone metastasis tissues were deeply sequenced using Arraystar human circRNA V2.0 microarray.

Techniques: Expressing, Quantitative RT-PCR, Binding Assay, Mutagenesis, Construct, Luciferase, Activity Assay, Transfection, shRNA

Study flow chart. First, the difference of circRNA expression profiles between anti‐tuberculosis drug‐induced liver injury (ADLI) and non‐ADLI patients were explored. Then, a differentially expressed circRNA was selected for verification in a cohort of 300 patients. Finally, the function of this circRNA was verified in a self‐controlled cohort of 35 patients based on the results of the experimental study

Journal: Journal of Cellular and Molecular Medicine

Article Title: Screening differential circular RNA expression profiles reveals the regulatory role of circMARS in anti‐tuberculosis drug‐induced liver injury

doi: 10.1111/jcmm.17157

Figure Lengend Snippet: Study flow chart. First, the difference of circRNA expression profiles between anti‐tuberculosis drug‐induced liver injury (ADLI) and non‐ADLI patients were explored. Then, a differentially expressed circRNA was selected for verification in a cohort of 300 patients. Finally, the function of this circRNA was verified in a self‐controlled cohort of 35 patients based on the results of the experimental study

Article Snippet: The circRNAs in the discovery cohort were profiled using the CapitalBio Technology CircRNA Human Gene Expression Microarray v2.0 (CapitalBio Technology, Beijing, China).

Techniques: Expressing

Identification of circRNA expression profiles in ADLI. (A) The scatter plots of circRNAs expression variations in the ADLI patients and in vitro assays. The red and green points in the plot indicate the upregulated and downregulated circRNAs. (B) Venn diagrams of the co‐expression circRNAs in the serum and cells. Two drugs: cells with Isoniazid (INH) + Rifampicin (RFP); three drugs: cells with INH + RFP + Pyrazinamide (PZA)

Journal: Journal of Cellular and Molecular Medicine

Article Title: Screening differential circular RNA expression profiles reveals the regulatory role of circMARS in anti‐tuberculosis drug‐induced liver injury

doi: 10.1111/jcmm.17157

Figure Lengend Snippet: Identification of circRNA expression profiles in ADLI. (A) The scatter plots of circRNAs expression variations in the ADLI patients and in vitro assays. The red and green points in the plot indicate the upregulated and downregulated circRNAs. (B) Venn diagrams of the co‐expression circRNAs in the serum and cells. Two drugs: cells with Isoniazid (INH) + Rifampicin (RFP); three drugs: cells with INH + RFP + Pyrazinamide (PZA)

Article Snippet: The circRNAs in the discovery cohort were profiled using the CapitalBio Technology CircRNA Human Gene Expression Microarray v2.0 (CapitalBio Technology, Beijing, China).

Techniques: Expressing, In Vitro